Stevanato Group SpA (STVN) 뉴스

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]

Stevanato Group Reports Financial Results for the First Quarter of 2024

Stevanato Group S.p.A. (NYSE: STVN), a leading global provider of drug containment, drug delivery, and diagnostic solutions to the...

Stevanato Group to Present at the Bank of America Securities Healthcare Conference

Stevanato Group S.p.A. (NYSE: STVN), a leading global provider of drug containment, drug delivery, and diagnostic solutions to the...

Stevanato Group to Report First Quarter 2024 Financial Results on May 9, 2024

Stevanato Group S.p.A. (NYSE: STVN), a leading global provider of drug containment, drug delivery, and diagnostic solutions to the...

Stevanato Group appoints Ugo Gay as Chief Operations Officer

Strengthening corporate leadership aims to drive operational efficiencies and standardization of global...

Stevanato Group Announces Closing of Upsized Public Offering of Ordinary Shares and Exercise in Full of the Underwriters’ Option to Purchase Additional Ordinary Shares

Stevanato Group S.p.A. (NYSE: STVN) (“Stevanato Group,” or the “Company”), a leading global provider of drug containment, drug delivery and...

Stevanato Group Announces Pricing of Upsized Public Offering of Ordinary Shares

Stevanato Group S.p.A. (NYSE: STVN) (“Stevanato Group,” or the “Company”), a leading global provider of drug containment, drug delivery and...

Stevanato Group Announces Public Offering of Ordinary Shares

Stevanato Group S.p.A. (NYSE: STVN) (“Stevanato Group,” or the “Company”), a leading global provider of drug containment, drug delivery and...

Stevanato Group to Present at the KeyBanc Capital Markets Virtual Life Sciences & MedTech Investor Forum

Stevanato Group S.p.A. (NYSE: STVN), a leading global provider of drug containment, drug delivery, and diagnostic solutions to the...

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]

Stevanato Group Delivers Double-Digit Revenue Growth in Fiscal Year 2023

- Establishes 2024 Guidance- Stevanato Group S.p.A. (NYSE: STVN), a leading global provider of drug containment, drug delivery, and diagnostic...

Stevanato Group to Report Fourth Quarter and Year End 2023 Financial Results on March 7, 2024

Stevanato Group S.p.A. (NYSE: STVN), a leading global provider of drug containment, drug delivery, and diagnostic solutions to the...

Stevanato Group Launches EZ-fill® Kit and Laboratory Fill and Finish Service to Support Small Batch Drug Development and Commercialization

New developments in the biopharmaceutical field fuel a need for highly scalable and flexible solutions...

Stevanato Group to Present at the 42nd Annual J.P. Morgan Healthcare Conference

Stevanato Group S.p.A. (NYSE: STVN), a leading global provider of drug containment, drug delivery, and diagnostic solutions to the...